Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam

Patients Undergoing Spine Surgery Clinical Trial

Official title: Comparison of Postoperative Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics (Propofol vs. Remimazolam) During Total Intravenous Anesthesia in the Spine Surgery Patients

Status Completed

Clinical Trial Summary

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Patients Undergoing Spine Surgery

• NCT number: NCT04994704
• Study type: Interventional
• Source: Gangnam Severance Hospital
• Status: Completed
• Phase: N/A
• Start date: December 1, 2021
• Completion date: July 12, 2023